I received this message from UCSF. I believe, soon they will stop using it everywhere else too.
In recent weeks, California has seen a rapid increase and dominance in circulation of COVID-19 Omicron subvariants which are resistant to our current monoclonal antibody treatment (bebtelovimab) and prophylaxis (tixagevimab/cilgavimab or Evusheld) options.
In light of this changing epidemiology, at UCSF we are no longer providing these therapeutics which are ineffective. UCSF Health has stopped scheduling new adult pts for Evusheld. Effective immediately, UCSF Health is canceling upcoming Evusheld appointments.
Your upcoming appointment for Evusheld has been cancelled. We will also contact you via a phone call with this information. We continue to recommend other effective prevention strategies for patients considered high-risk including: 1. Staying up-to-date with COVID-19 and flu vaccinations, including the bivalent booster2. Using high-quality masks or respirators when indoors in public3. Avoiding contact with individuals who exhibit signs of respiratory-like illnesses. When new therapeutics become available, we will update your team. Please send any questions to your clinical team.In good health,UCSF COVID-19 Therapeutics Task Force